Search research articles
Contact Us
Filters
Showing results (31-40 of 161) with videos related to
Page
of 17
Sort By:
Regulatory Peptides
|
December 17, 2008
Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice
Nigel Irwin, Kerry Hunter, Norma Frizzell, et al.
Biochimica Et Biophysica Acta. General Subjects
|
February 3, 2020
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction
Ryan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Diabetes, Obesity & Metabolism
|
July 18, 2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists
Neil Tanday, Ryan A Lafferty, Peter R Flatt, et al.
Diabetes/Metabolism Research and Reviews
|
September 27, 2014
Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes
Rachel Charlotte Moffett, Steven Patterson, Nigel Irwin, et al.
Metabolism: Clinical and Experimental
|
August 11, 2020
Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity
Ryan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Experimental Gerontology
|
December 23, 2006
Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice
Nigel Irwin, Paula L McClean, Patrick Harriott, et al.
Biochemical Pharmacology
|
May 4, 2020
Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance
Neil Tanday, Nigel Irwin, Peter R Flatt, et al.
Clinical Medicine Insights. Endocrinology and Diabetes
|
October 8, 2021
Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes
Aimee Coulter-Parkhill, Stephen McClean, Victor A Gault, et al.
European Journal of Pharmacology
|
November 18, 2009
Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline
Nigel Irwin, Peter R Flatt, Steven Patterson, et al.
The Journal of Endocrinology
|
March 5, 2020
Ψ-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance
Sarah L Craig, Victor A Gault, Gerd Hamscher, et al.
Page
of 17
Search research articles
Search
Showing results (31-40 of 161) with videos related to
Sort By:
Page
of 17
Regulatory Peptides
|
December 17, 2008
Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice
Nigel Irwin, Kerry Hunter, Norma Frizzell, et al.
Biochimica Et Biophysica Acta. General Subjects
|
February 3, 2020
Development and characterisation of a peptidergic N-and C-terminally stabilised mammalian NPY1R agonist which protects against diabetes induction
Ryan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Diabetes, Obesity & Metabolism
|
July 18, 2022
Beneficial metabolic effects of recurrent periods of beta-cell rest and stimulation using stable neuropeptide Y1 and glucagon-like peptide-1 receptor agonists
Neil Tanday, Ryan A Lafferty, Peter R Flatt, et al.
Diabetes/Metabolism Research and Reviews
|
September 27, 2014
Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes
Rachel Charlotte Moffett, Steven Patterson, Nigel Irwin, et al.
Metabolism: Clinical and Experimental
|
August 11, 2020
Generation and characterisation of C-terminally stabilised PYY molecules with potential in vivo NPYR2 activity
Ryan A Lafferty, Neil Tanday, Peter R Flatt, et al.
Experimental Gerontology
|
December 23, 2006
Beneficial effects of sub-chronic activation of glucagon-like peptide-1 (GLP-1) receptors on deterioration of glucose homeostasis and insulin secretion in aging mice
Nigel Irwin, Paula L McClean, Patrick Harriott, et al.
Biochemical Pharmacology
|
May 4, 2020
Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance
Neil Tanday, Nigel Irwin, Peter R Flatt, et al.
Clinical Medicine Insights. Endocrinology and Diabetes
|
October 8, 2021
Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes
Aimee Coulter-Parkhill, Stephen McClean, Victor A Gault, et al.
European Journal of Pharmacology
|
November 18, 2009
Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline
Nigel Irwin, Peter R Flatt, Steven Patterson, et al.
The Journal of Endocrinology
|
March 5, 2020
Ψ-Xenin-6 enhances sitagliptin effectiveness, but does not improve glucose tolerance
Sarah L Craig, Victor A Gault, Gerd Hamscher, et al.
Page
of 17